Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy-Reference-Cited by-同舟云学术

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy

Published:2021-12-28 Issue: Volume: Page:
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Maesaka Kazuki¹,Sakamori Ryotaro¹^ORCID,Yamada Ryoko¹,Tahata Yuki¹,Imai Yasuharu²,Ohkawa Kazuyoshi³^ORCID,Miyazaki Masanori⁴,Mita Eiji⁵,Ito Toshifumi⁶,Hagiwara Hideki⁷,Yakushijin Takayuki⁸,Kodama Takahiro¹^ORCID,Hikita Hayato¹^ORCID,Tatsumi Tomohide¹,Takehara Tetsuo¹^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Suita Osaka Japan

2. Department of Gastroenterology and Hepatology Ikeda Municipal Hospital Ikeda Osaka Japan

3. Department of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute Osaka Osaka Japan

4. Department of Gastroenterology and Hepatology Osaka Police Hospital Osaka Osaka Japan

5. Department of Gastroenterology and Hepatology National Hospital Organization Osaka National Hospital Osaka Osaka Japan

6. Department of Gastroenterology and Hepatology Japan Community Healthcare Organization Osaka Hospital Osaka Osaka Japan

7. Department of Gastroenterology and Hepatology Kansai Rosai Hospital Amagasaki Hyogo Japan

8. Department of Gastroenterology and Hepatology Osaka General Medical Center Osaka Osaka Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13741

Reference37 articles.

1. Sorafenib in Advanced Hepatocellular Carcinoma

2. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

4. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

5. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts;Cancers;2024-06-28

2. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment;International Immunopharmacology;2024-05

3. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis;BioScience Trends;2024-02-29

4. Incidence of immunotherapy‐related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta‐analysis;Cancer Medicine;2024-02

5. Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study;PLOS ONE;2024-01-02